TY - JOUR
T1 - Initial Results of Secukinumab Drug Survival in Patients with Psoriasis
T2 - A Multicentre Daily Practice Cohort Study
AU - van den Reek, Juul M P A
AU - van Vugt, Lieke J
AU - van Doorn, Martijn B A
AU - van der Kraaij, Gayle E
AU - de Kort, Wim J A
AU - Lucker, Georges P H
AU - Horvath, Barbara
AU - Njoo, M David
AU - Bovenschen, H Jorn
AU - Ossenkoppele, Paul M
AU - De Bruin-Weller, Marjolein S
AU - de Groot, Marjan
AU - Mommers, Roland
AU - Prevoo, Ruud L M A
AU - van de Kerkhof, Peter C M
AU - Spuls, Phyllis I
AU - Kievit, Wietske
AU - de Jong, Elke M G J
N1 - Publisher Copyright:
© 2018 Acta Dermato-Venereologica.
PY - 2018/7/11
Y1 - 2018/7/11
N2 - Interleukin 17-antagonist secukinumab demonstrated high efficacy for treatment of psoriasis in randomized controlled trials. However, performance in daily practice may differ from trials. Drug survival is a comprehensive outcome covering effectiveness and safety, suitable for analyses of daily practice. The aim of this study was to evaluate drug survival of secukinumab in a daily practice psoriasis cohort. Data were collected from 13 hospitals. Drug survival was analysed using Kaplan-Meier survival curves, split for reason of discontinuation. In total, 196 patients were included (83% biologic experienced). Overall, 12 and 18 months drug survival of secukinumab was 76% and 67%, respectively, and was mostly determined by ineffectiveness. There was a trend towards shorter drug survival in women and in biologic experienced patients. Thirteen percent of patients experienced at least one episode of fungal infection. This is one of the first studies of drug survival of secukinumab in patients with psoriasis treated in daily practice.
AB - Interleukin 17-antagonist secukinumab demonstrated high efficacy for treatment of psoriasis in randomized controlled trials. However, performance in daily practice may differ from trials. Drug survival is a comprehensive outcome covering effectiveness and safety, suitable for analyses of daily practice. The aim of this study was to evaluate drug survival of secukinumab in a daily practice psoriasis cohort. Data were collected from 13 hospitals. Drug survival was analysed using Kaplan-Meier survival curves, split for reason of discontinuation. In total, 196 patients were included (83% biologic experienced). Overall, 12 and 18 months drug survival of secukinumab was 76% and 67%, respectively, and was mostly determined by ineffectiveness. There was a trend towards shorter drug survival in women and in biologic experienced patients. Thirteen percent of patients experienced at least one episode of fungal infection. This is one of the first studies of drug survival of secukinumab in patients with psoriasis treated in daily practice.
KW - Adult
KW - Antibodies, Monoclonal, Humanized
KW - Antibodies, Monoclonal/adverse effects
KW - Dermatologic Agents/adverse effects
KW - Humans
KW - Kaplan-Meier Estimate
KW - Male
KW - Middle Aged
KW - Netherlands
KW - Proportional Hazards Models
KW - Psoriasis/diagnosis
KW - Retrospective Studies
KW - Time Factors
KW - Treatment Outcome
UR - http://www.scopus.com/inward/record.url?scp=85050094973&partnerID=8YFLogxK
U2 - 10.2340/00015555-2900
DO - 10.2340/00015555-2900
M3 - Article
C2 - 29405245
SN - 0001-5555
VL - 98
SP - 648
EP - 654
JO - Acta Dermato-Venereologica
JF - Acta Dermato-Venereologica
IS - 7
ER -